PURPOSE:Intensified intrathecal (i.t.) chemotherapy without cranial radiation therapy (CRT) prevents CNS relapse in children with low-risk and intermediate-risk acute lymphoblastic leukemia (ALL). In the current study, high-risk ALL patients who achieved a rapid early response (RER) to induction chemotherapy were randomized to receive intensive systemic chemotherapy and presymptomatic CNS therapy that consisted of either i.t. methotrexate (MTX) and CRT or intensified i.t. MTX alone. PATIENTS AND METHODS: Children (n = 636) with high-risk ALL (aged 1 to 9 years and WBC count > or = 50,000/microL or age > or = 10 years, excluding those with lymphomatous features) who achieved an RER (< or = 25% marrow blasts on day 7) to induction therapy and lacked CNS disease at diagnosis were randomized to receive systemic therapy with either i.t. MTX and CRT (regimen A, n = 317) or intensified i.t. MTX alone (regimen B, n = 319). RESULTS: Interim analysis in July 1993 revealed 3-year event-free survival (EFS) estimates of 82.1% +/- 4.0% (SD)and 70.4% +/- 4.2% for patients treated on regimens A and B, respectively (P = .004). As of January 1996, outcome had changed: 5-year EFS estimates were 69.1% +/- 3.4% and 75.0% +/- 2.7% for regimens A and B, respectively (P = 0.50). Marrow relapses comprised 57 events on regimen A and 43 events on regimen B. Fewer late events occurred on regimen B. CONCLUSION: For high-risk pediatric ALL patients who show an RER to induction therapy and are treated with systemic Children's Cancer Group (CCG)-modified Berlin-Frankfurt-Munster (BFM) chemotherapy, presymptomatic CNS therapy that consists of either i.t. MTX plus CRT or intensified i.t. MTX alone results in a similar 5-year EFS outcome. Furthermore, intensified i.t. MTX may protect against late bone marrow relapse.
RCT Entities:
PURPOSE: Intensified intrathecal (i.t.) chemotherapy without cranial radiation therapy (CRT) prevents CNS relapse in children with low-risk and intermediate-risk acute lymphoblastic leukemia (ALL). In the current study, high-risk ALL patients who achieved a rapid early response (RER) to induction chemotherapy were randomized to receive intensive systemic chemotherapy and presymptomatic CNS therapy that consisted of either i.t. methotrexate (MTX) and CRT or intensified i.t. MTX alone. PATIENTS AND METHODS: Children (n = 636) with high-risk ALL (aged 1 to 9 years and WBC count > or = 50,000/microL or age > or = 10 years, excluding those with lymphomatous features) who achieved an RER (< or = 25% marrow blasts on day 7) to induction therapy and lacked CNS disease at diagnosis were randomized to receive systemic therapy with either i.t. MTX and CRT (regimen A, n = 317) or intensified i.t. MTX alone (regimen B, n = 319). RESULTS: Interim analysis in July 1993 revealed 3-year event-free survival (EFS) estimates of 82.1% +/- 4.0% (SD)and 70.4% +/- 4.2% for patients treated on regimens A and B, respectively (P = .004). As of January 1996, outcome had changed: 5-year EFS estimates were 69.1% +/- 3.4% and 75.0% +/- 2.7% for regimens A and B, respectively (P = 0.50). Marrow relapses comprised 57 events on regimen A and 43 events on regimen B. Fewer late events occurred on regimen B. CONCLUSION: For high-risk pediatric ALL patients who show an RER to induction therapy and are treated with systemic Children's Cancer Group (CCG)-modified Berlin-Frankfurt-Munster (BFM) chemotherapy, presymptomatic CNS therapy that consists of either i.t. MTX plus CRT or intensified i.t. MTX alone results in a similar 5-year EFS outcome. Furthermore, intensified i.t. MTX may protect against late bone marrow relapse.
Authors: Stuart S Winter; Kimberly P Dunsmore; Meenakshi Devidas; Brent L Wood; Natia Esiashvili; Zhiguo Chen; Nancy Eisenberg; Nikki Briegel; Robert J Hayashi; Julie M Gastier-Foster; Andrew J Carroll; Nyla A Heerema; Barbara L Asselin; Paul S Gaynon; Michael J Borowitz; Mignon L Loh; Karen R Rabin; Elizabeth A Raetz; Patrick A Zweidler-Mckay; Naomi J Winick; William L Carroll; Stephen P Hunger Journal: J Clin Oncol Date: 2018-08-23 Impact factor: 44.544
Authors: María Sol Brassesco; Danilo Jordão Xavier; Marjori Leiva Camparoto; Ana Paula Montaldi; Paulo Roberto D'Auria Vieira de Godoy; Carlos Alberto Scrideli; Luiz Gonzaga Tone; Elza Tiemi Sakamoto-Hojo Journal: J Biomed Biotechnol Date: 2010-08-31
Authors: Stuart S Winter; Zeyu Jiang; Hadya M Khawaja; Timothy Griffin; Meenakshi Devidas; Barbara L Asselin; Richard S Larson Journal: Blood Date: 2007-05-10 Impact factor: 22.113
Authors: Nita L Seibel; Peter G Steinherz; Harland N Sather; James B Nachman; Cynthia Delaat; Lawrence J Ettinger; David R Freyer; Leonard A Mattano; Caroline A Hastings; Charles M Rubin; Kathy Bertolone; Janet L Franklin; Nyla A Heerema; Torrey L Mitchell; Allan F Pyesmany; Mei K La; Cheryl Edens; Paul S Gaynon Journal: Blood Date: 2007-11-26 Impact factor: 22.113
Authors: Kimberly P Dunsmore; Stuart S Winter; Meenakshi Devidas; Brent L Wood; Natia Esiashvili; Zhiguo Chen; Nancy Eisenberg; Nikki Briegel; Robert J Hayashi; Julie M Gastier-Foster; Andrew J Carroll; Nyla A Heerema; Barbara L Asselin; Karen R Rabin; Patrick A Zweidler-Mckay; Elizabeth A Raetz; Mignon L Loh; Kirk R Schultz; Naomi J Winick; William L Carroll; Stephen P Hunger Journal: J Clin Oncol Date: 2020-08-19 Impact factor: 44.544
Authors: Caroline Hastings; Paul S Gaynon; James B Nachman; Harland N Sather; Xiaomin Lu; Meenakshi Devidas; Nita L Seibel Journal: Br J Haematol Date: 2014-10-13 Impact factor: 6.998